Identification

Name
Imatinib
Accession Number
DB00619  (APRD01028, EXPT02967, DB03261)
Type
Small Molecule
Groups
Approved
Description

Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.

Structure
Thumb
Synonyms
  • 4-(4-METHYL-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
  • alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-P-toluidide
  • Imatinib
  • Imatinib Methansulfonate
  • Imatinibum
  • STI 571
External IDs
CGP-57148B / STI-571
Product Ingredients
IngredientUNIICASInChI Key
Imatinib Mesylate8A1O1M485B220127-57-1YLMAHDNUQAMNNX-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GleevecTablet100 mg/1OralNovartis Pharma Produktions Gmb H2001-05-15Not applicableUs
GleevecTablet400 mgOralNovartis2004-10-25Not applicableCanada
GleevecTablet400 mg/1OralNovartis2014-12-23Not applicableUs
GleevecTablet100 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
GleevecTablet100 mg/1OralNovartis2001-05-15Not applicableUs
GleevecCapsule100 mgOralNovartis2001-09-262008-09-24Canada
GleevecTablet100 mgOralNovartis2005-04-05Not applicableCanada
GleevecTablet400 mg/1OralNovartis2001-05-15Not applicableUs
GlivecCapsule50 mgOralNovartis Europharm Limited2001-11-07Not applicableEu
GlivecTablet, film coated400 mgOralNovartis Europharm Limited2001-11-07Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-imatinibTablet100 mgOralApotex Corporation2013-04-19Not applicableCanada
Apo-imatinibTablet400 mgOralApotex Corporation2013-04-19Not applicableCanada
Imatinib AccordTablet, film coated400 mgOralAccord Healthcare Limited2013-07-01Not applicableEu
Imatinib AccordTablet, film coated400 mgOralAccord Healthcare Limited2013-07-01Not applicableEu
Imatinib AccordTablet, film coated100 mgOralAccord Healthcare Limited2013-07-01Not applicableEu
Imatinib AccordTablet, film coated100 mgOralAccord Healthcare Limited2013-07-01Not applicableEu
Imatinib AccordTablet, film coated400 mgOralAccord Healthcare Limited2013-07-01Not applicableEu
Imatinib AccordTablet, film coated100 mgOralAccord Healthcare Limited2013-07-01Not applicableEu
Imatinib AccordTablet, film coated400 mgOralAccord Healthcare Limited2013-07-01Not applicableEu
Imatinib AccordTablet, film coated100 mgOralAccord Healthcare Limited2013-07-01Not applicableEu
International/Other Brands
Celonib (Celon) / Enliven (Orion) / Glivec (Novartis) / Imatib (Grey Inversiones) / Mesylonib (Miracalus) / Mitinab (Glenmark) / Plivatinib (Pliva) / Shantinib (Shantha)
Categories
UNII
BKJ8M8G5HI
CAS number
152459-95-5
Weight
Average: 493.6027
Monoisotopic: 493.259008649
Chemical Formula
C29H31N7O
InChI Key
KTUFNOKKBVMGRW-UHFFFAOYSA-N
InChI
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
IUPAC Name
N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide
SMILES
CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1

Pharmacology

Indication

For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).

Structured Indications
Pharmacodynamics

Imatinib is an antineoplastic agent used to treat chronic myelogenous leukemia. Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of Abl with Bcr (breakpoint cluster region), termed Bcr-Abl. As this is now a continuously active tyrosine kinase, Imatinib is used to decrease Bcr-Abl activity.

Mechanism of action

Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib also inhibits the receptor tyrosine kinases for platelet derived growth factor (PDGF) and stem cell factor (SCF) - called c-kit. Imatinib was identified in the late 1990s by Dr Brian J. Druker. Its development is an excellent example of rational drug design. Soon after identification of the bcr-abl target, the search for an inhibitor began. Chemists used a high-throughput screen of chemical libraries to identify the molecule 2-phenylaminopyrimidine. This lead compound was then tested and modified by the introduction of methyl and benzamide groups to give it enhanced binding properties, resulting in imatinib.

TargetActionsOrganism
ABCR/ABL fusion protein isoform X9
inhibitor
Human
AMast/stem cell growth factor receptor Kit
antagonist
multitarget
Human
ARET proto-oncogene
inhibitor
Human
UHigh affinity nerve growth factor receptor
antagonist
Human
UMacrophage colony-stimulating factor 1 receptor
antagonist
Human
UPlatelet-derived growth factor receptor alpha
antagonist
Human
UEpithelial discoidin domain-containing receptor 1
antagonist
Human
UTyrosine-protein kinase ABL1
inhibitor
Human
UPlatelet-derived growth factor receptor beta
antagonist
Human
Absorption

The pharmacokinetics in CML and GIST patients are similar. Imatinib is well absorbed with mean absolute bioavailability is 98% and maximum plasma levels achieved within 2-4 hours of dosing

Volume of distribution
Not Available
Protein binding

95% protein bound, mostly to albumin and alpha-1-acid glycoprotein.

Metabolism

Primarily hepatic via CYP3A4. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism. The main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. This metabolite is similar in potency to the parent compound.

Route of elimination

Imatinib elimination is predominately in the feces, mostly as metabolites. 81% of the dose is eliminated within 7 days, in feces (68% of the dose) and urine (13% of the dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% faces), the remainder being metabolites.

Half life

Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588) are approximately 18 and 40 hours, respectively.

Clearance
  • 8 L/h [50-year-old CML and GIST patient weighing 50 kg]
  • 14 L/h [50-year-old CML and GIST patient weighing 100 kg]
Toxicity

The most frequently reported adverse reactions (>30%) were edema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue and abdominal pain.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Imatinib Inhibition of BCR-ABLDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Imatinib can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Imatinib.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Imatinib.Approved
AcetaminophenAcetaminophen may increase the hepatotoxic activities of Imatinib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Imatinib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Imatinib.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Imatinib.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Imatinib.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Imatinib.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Imatinib.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Imatinib.Approved
AldosteroneThe serum concentration of Imatinib can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Imatinib can be increased when it is combined with Alectinib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Imatinib.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Imatinib.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Imatinib.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Imatinib.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Imatinib.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Imatinib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Imatinib.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Imatinib.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Imatinib.Approved, Illicit, Investigational
AmantadineThe serum concentration of Imatinib can be increased when it is combined with Amantadine.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Imatinib.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Imatinib.Approved
Aminohippuric acidThe serum concentration of Imatinib can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Imatinib.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Imatinib.Approved
AmiodaroneThe serum concentration of Imatinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Imatinib.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Imatinib.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Imatinib.Approved
AmsacrineThe serum concentration of Imatinib can be increased when it is combined with Amsacrine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Imatinib.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Imatinib.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Imatinib.Approved, Investigational
AprepitantThe serum concentration of Imatinib can be increased when it is combined with Aprepitant.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Imatinib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Imatinib.Approved, Investigational
ArmodafinilThe metabolism of Imatinib can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Imatinib.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Imatinib.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Imatinib.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Imatinib.Approved, Withdrawn
AtazanavirThe serum concentration of Imatinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Imatinib can be increased when it is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Imatinib can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Imatinib is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Imatinib.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Imatinib.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Imatinib.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Imatinib.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Imatinib.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Imatinib.Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Imatinib.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Imatinib.Approved, Investigational
BenzocaineThe serum concentration of Imatinib can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Imatinib.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Imatinib.Approved
BepridilThe serum concentration of Imatinib can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Imatinib.Approved, Vet Approved
BetaxololThe metabolism of Imatinib can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Imatinib.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Imatinib.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Imatinib.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Imatinib.Approved
BiperidenThe serum concentration of Imatinib can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Imatinib.Approved
BoceprevirThe serum concentration of Imatinib can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe serum concentration of Imatinib can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Imatinib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Imatinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imatinib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Imatinib.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Imatinib.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Imatinib.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Imatinib.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Imatinib.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Imatinib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Imatinib.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Imatinib.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Imatinib.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Imatinib can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Imatinib.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Imatinib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Imatinib.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Imatinib.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Imatinib.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Imatinib.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Imatinib.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Imatinib.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Imatinib.Approved
Candesartan cilexetilThe serum concentration of Imatinib can be increased when it is combined with Candesartan.Approved
CapecitabineThe metabolism of Imatinib can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Imatinib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Imatinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Imatinib.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Imatinib.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Imatinib.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Imatinib.Approved, Investigational
CaspofunginThe serum concentration of Imatinib can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Imatinib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Imatinib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Imatinib.Approved, Vet Approved
CeritinibThe serum concentration of Imatinib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Imatinib.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Imatinib.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Imatinib.Approved
ChloramphenicolThe metabolism of Imatinib can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Imatinib.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Imatinib.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Imatinib.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Imatinib.Approved, Vet Approved
ChlorpropamideThe serum concentration of Imatinib can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Imatinib can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Imatinib.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Imatinib.Approved, Nutraceutical
CholesterolThe serum concentration of Imatinib can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Imatinib can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Imatinib.Approved, Investigational
CilazaprilThe serum concentration of Imatinib can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Imatinib.Approved
CimetidineThe serum concentration of Imatinib can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Imatinib can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Imatinib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Imatinib.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Imatinib.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Imatinib.Approved
ClarithromycinThe serum concentration of Imatinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Imatinib can be increased when it is combined with Clemastine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Imatinib.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Imatinib.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Imatinib.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Imatinib.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Imatinib.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Imatinib.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Imatinib.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Imatinib.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Imatinib.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Imatinib.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Imatinib.Approved, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Imatinib.Approved
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Imatinib.Approved, Illicit
ClotrimazoleThe serum concentration of Imatinib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Imatinib is combined with Clozapine.Approved
CobicistatThe serum concentration of Imatinib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Imatinib.Approved
CocaineThe metabolism of Imatinib can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Imatinib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Imatinib.Approved
ColforsinThe serum concentration of Imatinib can be increased when it is combined with Colforsin.Experimental
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Imatinib.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Imatinib.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Imatinib.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Imatinib.Approved
CrisaboroleThe metabolism of Imatinib can be decreased when combined with Crisaborole.Approved
CrizotinibThe serum concentration of Imatinib can be increased when it is combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Imatinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Imatinib.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Imatinib.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Imatinib.Experimental
Cyproterone acetateThe serum concentration of Imatinib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Imatinib.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imatinib.Approved
DabrafenibThe serum concentration of Imatinib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Imatinib.Approved
DactinomycinThe serum concentration of Imatinib can be increased when it is combined with Dactinomycin.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Imatinib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Imatinib.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Imatinib.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Imatinib.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Imatinib.Approved, Investigational
DarunavirThe serum concentration of Imatinib can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Imatinib.Approved
DasatinibThe serum concentration of Imatinib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Imatinib.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Imatinib.Approved
DeferasiroxThe serum concentration of Imatinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Imatinib.Approved
DelavirdineThe serum concentration of Imatinib can be increased when it is combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Imatinib.Approved
DesipramineThe serum concentration of Imatinib can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Imatinib.Approved
DesloratadineThe serum concentration of Imatinib can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Imatinib.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Imatinib.Approved, Investigational
DexamethasoneThe serum concentration of Imatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Imatinib.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Imatinib.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Imatinib.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Imatinib.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Imatinib.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Imatinib.Approved, Vet Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Imatinib.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Imatinib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Imatinib.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Imatinib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Imatinib.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Imatinib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Imatinib.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Imatinib.Experimental
DihydroergotamineThe serum concentration of Imatinib can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Imatinib.Illicit
DiltiazemThe serum concentration of Imatinib can be increased when it is combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Imatinib can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Imatinib can be increased when it is combined with Dipyridamole.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Imatinib.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Imatinib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imatinib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Imatinib.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Imatinib.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Imatinib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Imatinib.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Imatinib.Approved
DosulepinThe metabolism of Imatinib can be decreased when combined with Dosulepin.Approved
DoxazosinThe serum concentration of Imatinib can be increased when it is combined with Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Imatinib.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Imatinib.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Imatinib.Approved, Investigational
DoxycyclineThe serum concentration of Imatinib can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Imatinib.Approved, Illicit
DronedaroneThe serum concentration of Imatinib can be increased when it is combined with Dronedarone.Approved
DuloxetineThe metabolism of Imatinib can be decreased when combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Imatinib.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Imatinib.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Imatinib.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Imatinib.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Imatinib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Imatinib.Approved
EltrombopagThe serum concentration of Imatinib can be increased when it is combined with Eltrombopag.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Imatinib.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Imatinib.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Imatinib.Approved
EnzalutamideThe serum concentration of Imatinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Imatinib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Imatinib.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Imatinib.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Imatinib.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Imatinib.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Imatinib.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Imatinib.Approved, Investigational
ErythromycinThe serum concentration of Imatinib can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Imatinib.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Imatinib can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Imatinib.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Imatinib.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Imatinib.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Imatinib.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Imatinib.Approved
EstriolThe serum concentration of Imatinib can be decreased when it is combined with Estriol.Approved, Vet Approved
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Imatinib.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Imatinib.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Imatinib.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Imatinib.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Imatinib.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Imatinib.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Imatinib.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Imatinib.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Imatinib.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Imatinib.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Imatinib.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Imatinib.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Imatinib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Imatinib.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Imatinib.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Imatinib.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Imatinib.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Imatinib.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Imatinib.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Imatinib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Imatinib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imatinib.Approved
FexofenadineThe serum concentration of Imatinib can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Imatinib.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Imatinib.Approved
FingolimodImatinib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Imatinib.Approved
FloxuridineThe metabolism of Imatinib can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Imatinib can be increased when it is combined with Fluconazole.Approved
FludarabineImatinib may decrease the myelosuppressive activities of Fludarabine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Imatinib.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Imatinib.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Imatinib.Approved
FluorouracilThe metabolism of Imatinib can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Imatinib can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Imatinib can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Imatinib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Imatinib.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Imatinib.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Imatinib.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be decreased when combined with Imatinib.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Imatinib.Approved
FluvoxamineThe serum concentration of Imatinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Imatinib can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Imatinib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Imatinib can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Imatinib.Approved, Investigational
Fusidic AcidThe serum concentration of Imatinib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Imatinib.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Imatinib.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Imatinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Imatinib.Approved
GemfibrozilThe serum concentration of the active metabolites of Imatinib can be reduced when Imatinib is used in combination with Gemfibrozil resulting in a loss in efficacy.Approved
GenisteinThe serum concentration of Imatinib can be increased when it is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Imatinib.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Imatinib.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Imatinib.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Imatinib.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Imatinib.Approved
GlycerinThe serum concentration of Imatinib can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Imatinib can be increased when it is combined with Gramicidin D.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Imatinib.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Imatinib.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Imatinib.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Imatinib.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Imatinib.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Imatinib.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Imatinib.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Imatinib.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Imatinib.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Imatinib.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Imatinib.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Imatinib.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Imatinib.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Imatinib.Approved
IbuprofenThe serum concentration of Imatinib can be decreased when it is combined with Ibuprofen.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Imatinib.Approved, Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Imatinib resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Imatinib.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Imatinib.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Imatinib.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Imatinib.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Imatinib.Approved
IndinavirThe serum concentration of Imatinib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Imatinib can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Imatinib.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Imatinib.Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Imatinib.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Imatinib.Approved
IrbesartanThe metabolism of Imatinib can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Imatinib.Approved, Investigational
IsavuconazoniumThe serum concentration of Imatinib can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Imatinib can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Imatinib.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Imatinib.Approved
IsradipineThe serum concentration of Imatinib can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Imatinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Imatinib.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Imatinib.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Imatinib.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Imatinib.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Imatinib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Imatinib.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Imatinib.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Imatinib.Approved
KetoconazoleThe serum concentration of Imatinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Imatinib.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Imatinib.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Imatinib.Experimental
LansoprazoleLansoprazole may increase the dermatologic adverse activities of Imatinib.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Imatinib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Imatinib.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Imatinib.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Imatinib is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Imatinib.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Imatinib.Approved
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Imatinib.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Imatinib.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Imatinib.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Imatinib.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Imatinib.Approved
LevofloxacinThe serum concentration of Imatinib can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Imatinib.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Imatinib.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Imatinib.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Imatinib.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Imatinib.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Imatinib.Approved
LiothyronineThe serum concentration of Imatinib can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Imatinib can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Imatinib can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Imatinib.Approved
LobeglitazoneThe metabolism of Imatinib can be decreased when combined with Lobeglitazone.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Imatinib.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Imatinib.Approved
LopinavirThe serum concentration of Imatinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Imatinib.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Imatinib.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Imatinib.Approved
LovastatinThe serum concentration of Imatinib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Imatinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Imatinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Imatinib.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Imatinib.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Imatinib.Illicit, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Imatinib.Approved
ManidipineThe metabolism of Imatinib can be decreased when combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Imatinib.Approved, Investigational
MaprotilineThe serum concentration of Imatinib can be increased when it is combined with Maprotiline.Approved
MaravirocThe metabolism of Maraviroc can be decreased when combined with Imatinib.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Imatinib.Approved, Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Imatinib.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Imatinib.Approved
Megestrol acetateThe serum concentration of Imatinib can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Imatinib.Approved, Vet Approved
MeprobamateThe serum concentration of Imatinib can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Imatinib.Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Imatinib.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Imatinib.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Imatinib.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Imatinib.Approved
MethotrimeprazineThe metabolism of Imatinib can be decreased when combined with Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Imatinib.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Imatinib.Approved, Vet Approved
Methyl salicylateThe metabolism of Methyl salicylate can be decreased when combined with Imatinib.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Imatinib.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Imatinib.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Imatinib.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Imatinib.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Imatinib.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Imatinib.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Imatinib.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Imatinib.Experimental
MexiletineThe metabolism of Imatinib can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Imatinib.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Imatinib.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Imatinib.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Imatinib.Approved, Illicit
MidostaurinThe metabolism of Imatinib can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Imatinib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Imatinib.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Imatinib.Approved
MitomycinThe serum concentration of Imatinib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Imatinib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Imatinib can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Imatinib can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Imatinib.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Imatinib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Imatinib.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Imatinib.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Imatinib.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Imatinib.Approved, Vet Approved
NaltrexoneThe serum concentration of Imatinib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Imatinib can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Imatinib is combined with Natalizumab.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Imatinib.Approved, Investigational
NefazodoneThe serum concentration of Imatinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Imatinib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Imatinib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Imatinib.Approved, Investigational
NetupitantThe serum concentration of Imatinib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Imatinib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Imatinib can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Imatinib.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Imatinib.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Imatinib.Approved
NilotinibThe serum concentration of Imatinib can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Imatinib.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Imatinib.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Imatinib.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Imatinib.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Imatinib.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Imatinib.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Imatinib.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Imatinib.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Imatinib.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Imatinib.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Imatinib.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Imatinib.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Imatinib.Experimental
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Imatinib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Imatinib.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Imatinib.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Imatinib.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Imatinib.Approved
OsimertinibThe serum concentration of Imatinib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Imatinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Imatinib.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Imatinib.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Imatinib.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Imatinib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Imatinib.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Imatinib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Imatinib.Approved, Vet Approved
PalbociclibThe serum concentration of Imatinib can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Imatinib can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Imatinib.Approved, Investigational
PanobinostatThe serum concentration of Imatinib can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Imatinib.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Imatinib.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Imatinib.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Imatinib.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Imatinib.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Imatinib.Approved
ParoxetineThe metabolism of Imatinib can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Imatinib.Approved
Peginterferon alfa-2bThe serum concentration of Imatinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Imatinib.Approved
PentobarbitalThe serum concentration of Imatinib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Imatinib.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Imatinib.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Imatinib.Approved
PerindoprilThe serum concentration of Imatinib can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Imatinib.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Imatinib.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Imatinib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Imatinib.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Imatinib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Imatinib.Withdrawn
PhenobarbitalThe serum concentration of Imatinib can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Imatinib.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Imatinib.Approved
PhenytoinThe serum concentration of Imatinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Imatinib.Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Imatinib.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Imatinib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Imatinib.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Imatinib.Withdrawn
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Imatinib.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Imatinib.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Imatinib.Approved
Platelet Activating FactorThe serum concentration of Imatinib can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Imatinib.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Imatinib.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Imatinib.Approved
PosaconazoleThe serum concentration of Imatinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Imatinib.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Imatinib.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Imatinib.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Imatinib.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Imatinib.Approved, Vet Approved
PrazosinThe serum concentration of Imatinib can be increased when it is combined with Prazosin.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Imatinib.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Imatinib.Approved, Vet Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Imatinib.Approved
PrimidoneThe serum concentration of Imatinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Imatinib can be increased when it is combined with Probenecid.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Imatinib.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Imatinib.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Imatinib.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Imatinib.Approved, Vet Approved
PromethazineThe serum concentration of Imatinib can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may increase the hepatotoxic activities of Imatinib.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Imatinib.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Imatinib.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Imatinib.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Imatinib.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Imatinib.Experimental
ProtriptylineThe serum concentration of Imatinib can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Imatinib.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Imatinib.Approved
PyrimethamineThe metabolism of Imatinib can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Imatinib.Approved, Illicit
QuercetinThe serum concentration of Imatinib can be increased when it is combined with Quercetin.Experimental
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Imatinib.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Imatinib.Approved
QuinidineThe metabolism of Imatinib can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Imatinib.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Imatinib.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Imatinib is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Imatinib.Approved
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Imatinib.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Imatinib.Approved, Investigational
RanitidineThe serum concentration of Imatinib can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Imatinib.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Imatinib.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Imatinib.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Imatinib.Approved, Investigational
ReserpineThe serum concentration of Imatinib can be decreased when it is combined with Reserpine.Approved
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Imatinib.Approved
RifabutinThe serum concentration of Imatinib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Imatinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Imatinib can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Imatinib.Approved, Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Imatinib.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Imatinib.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Imatinib.Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Imatinib.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Imatinib.Approved, Investigational
RitonavirThe serum concentration of Imatinib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Imatinib.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Imatinib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Imatinib.Approved
RolapitantThe serum concentration of Imatinib can be increased when it is combined with Rolapitant.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Imatinib.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Imatinib.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Imatinib.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Imatinib.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Imatinib.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Imatinib.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Imatinib.Approved, Withdrawn
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Imatinib.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Imatinib.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Imatinib.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Imatinib.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Imatinib.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Imatinib.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Imatinib.Approved
SaquinavirThe serum concentration of Imatinib can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Imatinib.Approved
ScopolamineThe serum concentration of Imatinib can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Imatinib can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Imatinib.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Imatinib.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Imatinib.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Imatinib.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Imatinib.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Imatinib.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Imatinib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Imatinib can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Imatinib.Approved
SiltuximabThe serum concentration of Imatinib can be decreased when it is combined with Siltuximab.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Imatinib.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Imatinib.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Imatinib.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Imatinib.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Imatinib.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Imatinib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Imatinib.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Imatinib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Imatinib.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Imatinib.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Imatinib.Approved
SpironolactoneThe serum concentration of Imatinib can be increased when it is combined with Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Imatinib.Investigational
St. John's WortThe metabolism of Imatinib can be increased when combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Imatinib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Imatinib can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Imatinib can be decreased when it is combined with Streptozocin.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Imatinib.Approved, Investigational
SulfadiazineThe metabolism of Imatinib can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Imatinib.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Imatinib.Approved
SulfisoxazoleThe serum concentration of Imatinib can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Imatinib is combined with Sulpiride.Approved
SumatriptanThe serum concentration of Imatinib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Imatinib.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Imatinib.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Imatinib.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Imatinib.Approved
TacrineThe serum concentration of Imatinib can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Imatinib.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Imatinib.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Imatinib.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Imatinib.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Imatinib.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Imatinib.Experimental
Taurocholic AcidThe serum concentration of Imatinib can be increased when it is combined with Taurocholic Acid.Experimental
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Imatinib.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Imatinib.Approved
TelaprevirThe serum concentration of Imatinib can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Imatinib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Imatinib can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Imatinib.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Imatinib.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Imatinib.Approved
Tenofovir disoproxilThe metabolism of Imatinib can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe serum concentration of Imatinib can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Imatinib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Imatinib.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Imatinib.Experimental
TeriflunomideThe serum concentration of Imatinib can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Imatinib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Imatinib.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Imatinib.Approved, Vet Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Imatinib.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Imatinib.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Imatinib.Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Imatinib.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Imatinib.Approved
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Imatinib.Approved
TiclopidineThe serum concentration of Imatinib can be increased when it is combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Imatinib.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Imatinib.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Imatinib.Approved
TipranavirThe metabolism of Imatinib can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Imatinib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibImatinib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolbutamideThe metabolism of Imatinib can be decreased when combined with Tolbutamide.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Imatinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Imatinib.Approved
TopiramateThe metabolism of Imatinib can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Imatinib can be decreased when combined with Topiroxostat.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Imatinib.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Imatinib.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Imatinib.Approved, Investigational
TranylcypromineThe metabolism of Imatinib can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Imatinib.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Imatinib.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Imatinib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Imatinib.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Imatinib.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Imatinib.Approved
TrifluoperazineThe serum concentration of Imatinib can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Imatinib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Imatinib.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Imatinib.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Imatinib.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Imatinib.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Imatinib.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Imatinib.Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Imatinib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Imatinib.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Imatinib.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Imatinib.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Imatinib.Investigational, Withdrawn
Valproic AcidThe metabolism of Imatinib can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Imatinib can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Imatinib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Imatinib.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Imatinib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Imatinib.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Imatinib.Approved
VemurafenibThe serum concentration of Imatinib can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Imatinib.Approved
VenlafaxineThe serum concentration of Imatinib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Imatinib can be increased when it is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Imatinib.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Imatinib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Imatinib.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Imatinib.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Imatinib.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Imatinib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Imatinib.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Imatinib.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Imatinib.Approved
VoriconazoleThe serum concentration of Imatinib can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Imatinib.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Imatinib.Approved
WarfarinImatinib may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Imatinib.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Imatinib.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Imatinib.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Imatinib.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Imatinib.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Imatinib.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Imatinib.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Imatinib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Imatinib can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Imatinib.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Imatinib.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Imatinib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Imatinib.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Imatinib.Approved
ZucapsaicinThe metabolism of Imatinib can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Imatinib.Approved, Investigational
Food Interactions
  • Take with food to reduce the incidence of gastric irritation. Follow with a large glass of water. A lipid rich meal will slightly reduce and delay absorption. Avoid grapefruit and grapefruit juice throughout treatment, grapefruit can significantly increase serum levels of this product.

References

Synthesis Reference
US5521184
General References
  1. Deininger MW, Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003 Sep;55(3):401-23. Epub 2003 Jul 17. [PubMed:12869662]
  2. Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001 Feb;7(2):228-34. [PubMed:11175855]
  3. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL: Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51. [PubMed:16779792]
  4. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 May;24(5):935-42. Epub 2004 Feb 26. [PubMed:14988091]
  5. Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D: Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med. 2005 Jul;11(7):731-9. Epub 2005 Jun 26. [PubMed:15980865]
External Links
Human Metabolome Database
HMDB14757
KEGG Drug
D01441
PubChem Compound
5291
PubChem Substance
46505055
ChemSpider
5101
BindingDB
13530
ChEBI
45783
ChEMBL
CHEMBL941
Therapeutic Targets Database
DNC001383
PharmGKB
PA10804
HET
STI
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Imatinib
ATC Codes
L01XE01 — Imatinib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
  • 92:00.00 — Miscellaneous Therapeutic Agents
PDB Entries
1iep / 1opj / 1t46 / 1xbb / 2hyy / 2oiq / 2pl0 / 3fw1 / 3gvu / 3hec
show 8 more
FDA label
Download (129 KB)
MSDS
Download (217 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentChronic Myeloid Leukemia (CML)1
1Active Not RecruitingTreatmentLeukemias1
1Active Not RecruitingTreatmentMalignancies, Hematologic1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Undifferentiated Leukemia (AUL) / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Primary CNS Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blastic Phase Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Gastrointestinal Stromal Tumors / Intraocular Lymphoma / Isolated Plasmacytoma of Bone / Leukemia, Prolymphocytic / Meningeal Chronic Myelogenous Leukemia / Monoclonal Gammopathy of Undetermined Significance (MGUS) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Central Nervous System Non-Hodgkin Lymphoma / Primary Myelofibrosis / Primary Systemic Amyloidosis / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Unspecified Adult Solid Tumor, Protocol Specific / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentAdvanced Pancreatic Cancer1
1CompletedTreatmentBrain and Central Nervous System Tumors2
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentChronic Myelogenous Leukemia (CML)1
1CompletedTreatmentChronic Myeloid Leukemia (CML)2
1CompletedTreatmentChronic Myeloid Leukemia (CML) / Gastrointestinal Stromal Tumors1
1CompletedTreatmentGastrointestinal Stromal Tumors1
1CompletedTreatmentGlioblastomas / Gliosarcoma2
1CompletedTreatmentHealthy Volunteers5
1CompletedTreatmentLeukemia,Myeloid, Chronic1
1CompletedTreatmentLeukemias6
1CompletedTreatmentLung Cancers2
1CompletedTreatmentMalignant Neoplasm of Stomach1
1CompletedTreatmentMesothelioma1
1CompletedTreatmentNeoplasms, Malignant / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentProstate Cancer2
1CompletedTreatmentRefractory Malignancy / Tumors, Solid1
1CompletedTreatmentThymic Carcinoma1
1CompletedTreatmentUnspecified Adult Solid Tumor1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1RecruitingHealth Services ResearchChronic Myelogenous Leukemia (CML) / Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAdvanced Cancers1
1TerminatedNot AvailableChronic Myeloid Leukemia (CML) / Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN) / Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)1
1TerminatedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Relapsing Chronic Myelogenous Leukemia1
1TerminatedTreatmentAdvanced Colorectal Cancer1
1TerminatedTreatmentGastrointestinal Stromal Tumors1
1TerminatedTreatmentMalignant Neoplasm of Pancreas1
1Unknown StatusTreatmentChordomas1
1Unknown StatusTreatmentGraft Versus Host Disease (GVHD)1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentHealthy Volunteers1
1WithdrawnTreatmentPulmonary Hypertension (PH)1
1, 2Active Not RecruitingTreatmentAdult Anaplastic Oligodendroglioma / Adult Mixed Glioma / Adult Oligodendroglioma / Recurrent Adult Brain Neoplasm / Recurrent Adult Brain Tumor1
1, 2Active Not RecruitingTreatmentAdvanced Gastrointestinal Stromal Tumor (GIST)1
1, 2Active Not RecruitingTreatmentAdvanced Melanoma / Melanoma1
1, 2Active Not RecruitingTreatmentNeurofibromas / Neurofibromatosis1
1, 2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Relapsing Chronic Myelogenous Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Myelogenous Leukemia (CML)1
1, 2CompletedTreatmentAcute Undifferentiated Leukemia (AUL) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / L1 Adult Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Adult Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentAdult Synovial Sarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
1, 2CompletedTreatmentAlveolitis / Sclerosis, Progressive Systemic1
1, 2CompletedTreatmentBlastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Relapsing Chronic Myelogenous Leukemia1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentCancer, Ovarian / Endometrial Cancers / Gastrointestinal Stromal Tumors / Sarcomas / Small Intestine Cancer1
1, 2CompletedTreatmentClear Cell Renal Cell Carcinoma1
1, 2CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
1, 2CompletedTreatmentDermatofibrosarcoma1
1, 2CompletedTreatmentDesmoid Tumors1
1, 2CompletedTreatmentGastrointestinal Stromal Tumors1
1, 2CompletedTreatmentLeukemia, Myelogenous, Chronic, BCR-ABL Positive1
1, 2CompletedTreatmentLeukemias6
1, 2CompletedTreatmentRecurrent Melanoma / Stage III Melanoma / Stage IV Melanoma / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentRefractory Desmoplastic Small Round Cell Tumors1
1, 2CompletedTreatmentScleroderma, Systemic1
1, 2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
1, 2CompletedTreatmentStage IV Colorectal Cancer1
1, 2CompletedTreatmentUterine Cancers1
1, 2Not Yet RecruitingTreatmentLymphangioleiomyomatosis1
1, 2RecruitingTreatmentALK+ Anaplastic Large Cell Lymphoma1
1, 2RecruitingTreatmentGastrointestinal Stromal Tumors (GISTs)1
1, 2RecruitingTreatmentPlasmodium Falciparum Malaria1
1, 2RecruitingTreatmentStage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
1, 2TerminatedTreatmentBrain and Central Nervous System Tumors1
1, 2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2TerminatedTreatmentChronic Myeloid Leukemia (CML)1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia1
1, 2TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1
1, 2TerminatedTreatmentThyroid Cancers / Tumors, Solid1
1, 2Unknown StatusTreatmentLeukemias1
1, 2WithdrawnTreatmentChronic Myeloid Leukemia (CML)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Relapsing Chronic Myelogenous Leukemia1
2Active Not RecruitingTreatmentAdvanced Chondrosarcoma / Advanced Desmoid Tumor1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentChronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase of Disease1
2Active Not RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2Active Not RecruitingTreatmentChronic Phase Chronic Myeloid Leukemia1
2Active Not RecruitingTreatmentDiabetes Mellitus, Insulin-Dependent, 1 / Diabetes, Diabetes Mellitus Type 1 / Insulin-Dependent Diabetes Mellitus 1 / Type 1 Insulin-Dependent Diabetes Mellitus1
2Active Not RecruitingTreatmentFibromatosis1
2Active Not RecruitingTreatmentGastrointestinal Stromal Tumors (GISTs)1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentMesothelioma, Malignant1
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentPulmonary Veno Occlusive Disease1
2Active Not RecruitingTreatmentTransplantation, Stem Cell / Treatments1
2CompletedNot AvailableDermatofibrosarcoma Protuberans1
2CompletedPreventionGastrointestinal Stromal Tumors1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Relapsing Chronic Myelogenous Leukemia1
2CompletedTreatmentAcral Lentiginous Malignant Melanoma / Recurrent Melanoma / Stage IIIA Melanoma / Stage IIIB Melanoma / Stage IIIc Melanoma / Stage IV Melanoma1
2CompletedTreatmentAcral/Lentiginous Melanoma / Chronically Sun Damaged Melanomas / Mucosal Melanoma1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)3
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Cromosome Philadelphia Positive1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Philadelphia Chromosome1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission1
2CompletedTreatmentAdult Fibrosarcoma / Dermatofibrosarcoma Protuberans / Recurrent Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentAdult Grade I Meningioma / Adult Grade II Meningioma / Adult Grade III Meningioma / Adult Meningeal Hemangiopericytoma / Adult Meningioma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdvanced Gastrointestinal Stromal Tumors1
2CompletedTreatmentAdvanced or Metastatic Cholangiocellular Carcinoma and Bile Duct1
2CompletedTreatmentAgnogenic Myeloid Metaplasia / Chronic Myelomonocytic Leukemia / Myeloid Metaplasia1
2CompletedTreatmentAntineoplastic Agents / Genital Diseases, Male / Genital Neoplasms, Male / Genitourinary tract neoplasm / Imatinib / Neoplasms / Neoplasms, Abdominal / Prostatic Diseases / Prostatic Neoplasms1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentBlast Crisis / Leukemia, Lymphocytic, Acute / Leukemia,Myeloid, Chronic / Philadelphia Chromosome1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentCML / Imatinib1
2CompletedTreatmentCancer, Breast3
2CompletedTreatmentCancer, Ovarian2
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cancer1
2CompletedTreatmentCancers / Leukemia, Other1
2CompletedTreatmentChildhood Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia1
2CompletedTreatmentChildhood Desmoplastic Small Round Cell Tumor / Childhood Synovial Sarcoma / Gastrointestinal Stromal Tumors / Lung Cancer Metastatic / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Neuroblastoma / Recurrent Osteosarcoma1
2CompletedTreatmentChildhood Malignant Fibrous Histiocytoma of Bone / Sarcomas1
2CompletedTreatmentChordomas1
2CompletedTreatmentChronic Eosinophilic Leukemia (CEL) / Chronic Idiopathic Hypereosinophilia / Hypereosinophilic Syndromes1
2CompletedTreatmentChronic Myelogenous Leukemia (CML)1
2CompletedTreatmentChronic Myelogenous Leukemia (CML) / Chronic Myelomonocytic Leukemia1
2CompletedTreatmentChronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Relapsing Chronic Myelogenous Leukemia1
2CompletedTreatmentChronic Myeloid Leukemia (CML)5
2CompletedTreatmentChronic Myeloid Leukemia (CML) / Minimal Residual Disease1
2CompletedTreatmentChronic Myeloid Leukemia (CML) / Philadelphia-Positive Myeloid Leukemia1
2CompletedTreatmentChronic Myelomonocytic Leukemia / Dermatofibrosarcoma / Hypereosinophilic Syndromes / Systemic Mastocytosis1
2CompletedTreatmentChronic Myelomonocytic Leukemia / Essential Thrombocythemia (ET) / Polycythemia Vera (PV) / Primary Myelofibrosis1
2CompletedTreatmentDesmoid Tumors / Fibromatosis, Aggressive1
2CompletedTreatmentGastrointestinal Stromal Tumors8
2CompletedTreatmentGastrointestinal Stromal Tumors (GISTs)1
2CompletedTreatmentGastrointestinal Stromal Tumors / Metastatic Cancers1
2CompletedTreatmentGastrointestinal Stromal Tumors / Sarcomas1
2CompletedTreatmentGlioblastomas / Gliosarcoma1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Scleroderma, Systemic1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHead and Neck Carcinoma / Squamous Cell Cancer1
2CompletedTreatmentHealth Care Evaluation / Health Care Quality1
2CompletedTreatmentImatinib Mesylate / Sclerotic Graft Versus Host Disease1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2CompletedTreatmentLeukemia, Myeloid, Chronic-Phase1
2CompletedTreatmentLeukemias12
2CompletedTreatmentLife Threatening Diseases1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentLung Cancers4
2CompletedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMalignant Pleural Effusions / Recurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentMelanoma / Skin Neoplasms1
2CompletedTreatmentMetastatic Cancers / Prostate Cancer2
2CompletedTreatmentMetastatic Melanoma1
2CompletedTreatmentMyelodysplastic Syndromes / Myeloid Leukemias1
2CompletedTreatmentMyeloid Leukemia, Chronic, Chronic-Phase1
2CompletedTreatmentNeurofibromatosis1
2CompletedTreatmentPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia1
2CompletedTreatmentPhiladelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia2
2CompletedTreatmentPhiladelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis1
2CompletedTreatmentPolycythemia Vera (PV)2
2CompletedTreatmentPrimary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2CompletedTreatmentPrimary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentRecurrent Gastric Cancer / Stage IV Gastric Cancer1
2CompletedTreatmentRecurrent Neuroendocrine Carcinoma of the Skin / Stage II Neuroendocrine Carcinoma of the Skin / Stage III Neuroendocrine Carcinoma of the Skin1
2CompletedTreatmentRecurrent Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Uterine Sarcoma / Uterine Carcinosarcoma1
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentSarcomas3
2CompletedTreatmentScleroderma, Localized / Scleroderma, Systemic1
2CompletedTreatmentSystemic Sclerosis, Scleroderma1
2CompletedTreatmentT Cell Non-Hodgkin's Lymphoma1
2CompletedTreatmentUnresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)1
2Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent B Lymphoblastic Lymphoma / Recurrent T Lymphoblastic Leukemia/Lymphoma / Refractory B Lymphoblastic Lymphoma / Refractory T Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
2Not Yet RecruitingTreatmentLeukemia, Myelogenous, Chronic, BCR-ABL Positive1
2Not Yet RecruitingTreatmentLoaisis1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / CD20 Positive / Philadelphia Chromosome Positive1
2RecruitingTreatmentAdvanced, Refractory Cancer1
2RecruitingTreatmentChronic Graft Versus Host Disease1
2RecruitingTreatmentChronic Myelogenous Leukemia (CML) / Chronic Myeloid Leukemia (CML) / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemias1
2RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2RecruitingTreatmentChronic Myeloid Leukemia (CML) / Philadelphia Chromosome Positive CML1
2RecruitingTreatmentColonic Neoplasms1
2RecruitingTreatmentGastrointestinal Stromal Tumors1
2RecruitingTreatmentGastrointestinal Stromal Tumors (GISTs)1
2RecruitingTreatmentGastrointestinal Stromal Tumours1
2RecruitingTreatmentHypereosinophilic Syndromes1
2RecruitingTreatmentLeukemias1
2RecruitingTreatmentPlexiform Neurofibromas1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2SuspendedTreatmentAcute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2TerminatedTreatmentBlast Phase / Chronic Myelocytic Leukemia / Myeloid Leukemia, Chronic, Accelerated-Phase / Myeloid Leukemia, Chronic, Chronic-Phase1
2TerminatedTreatmentCancer Brain / Cancers / Gastrointestinal Stromal Tumors / Tumors, Solid1
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentCancers1
2TerminatedTreatmentChronic Myelocytic Leukemia1
2TerminatedTreatmentChronic Myelogenous Leukemia (CML)1
2TerminatedTreatmentChronic Myeloproliferative Disorders1
2TerminatedTreatmentGIST / Metastatic Disease1
2TerminatedTreatmentGastric Adenocarcinoma1
2TerminatedTreatmentGastrointestinal Stromal Tumors1
2TerminatedTreatmentGlioblastomas1
2TerminatedTreatmentHypereosinophilic Syndromes1
2TerminatedTreatmentLeukemia,Myeloid, Chronic1
2TerminatedTreatmentLeukemias5
2TerminatedTreatmentLeukemias / Malignant Lymphomas1
2TerminatedTreatmentLung Cancers1
2TerminatedTreatmentMelanoma1
2TerminatedTreatmentMetastatic Melanoma1
2TerminatedTreatmentMyelogenous Leukemia, Chronic, Chronic Phase1
2TerminatedTreatmentOvarian Dysgerminoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Ovarian Germ Cell Tumor / Stage II Malignant Testicular Germ Cell Tumor / Stage II Ovarian Germ Cell Tumor / Stage III Malignant Testicular Germ Cell Tumor / Stage III Ovarian Germ Cell Tumor / Testicular Seminoma1
2TerminatedTreatmentPulmonary Hypertension (PH)1
2TerminatedTreatmentRecurrent Glioblastoma Multiforme (GBM)1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentScleroderma1
2TerminatedTreatmentThyroid Cancers1
2Unknown StatusNot AvailableAcute Lymphocytic Leukemia (ALL)1
2Unknown StatusNot AvailableChronic Myeloid Leukemia (CML)1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors1
2Unknown StatusTreatmentCancers of the Head and Neck / Carcinoma, Adenoid Cystic1
2Unknown StatusTreatmentCervical Spinal Cord Injury1
2Unknown StatusTreatmentChronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)1
2Unknown StatusTreatmentGastrointestinal Stromal Tumors1
2Unknown StatusTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2Unknown StatusTreatmentLeukemias3
2Unknown StatusTreatmentLymphoid Blastic Phase of Chronic Myeloid Leukemia / Philadelphia Positive Acute Lymphoblastic Leukemia1
2Unknown StatusTreatmentMelanoma1
2Unknown StatusTreatmentMyelogenous Leukemia, Chronic1
2Unknown StatusTreatmentNephrogenic Systemic Fibrosis1
2Unknown StatusTreatmentSclerosis, Progressive Systemic2
2WithdrawnTreatmentChronic Myelogenous Leukemia (CML)1
2WithdrawnTreatmentChronic Myeloid Leukemia, Blast Crisis / Leukemia Acute Myeloid Leukemia (AML)1
2WithdrawnTreatmentEosinophilia / Hypereosinophilic Syndromes1
2WithdrawnTreatmentMetastatic Solid Tumors1
2, 3CompletedEducational/Counseling/TrainingChronic Lung Diseases / Idiopathic Pulmonary Fibrosis (IPF) / Pulmonary Fibrosis1
2, 3CompletedTreatmentChronic Myeloid Leukemia (CML) / Gastrointestinal Stromal Tumors1
2, 3CompletedTreatmentPulmonary Arterial Hypertension (PAH)1
2, 3TerminatedTreatmentMalignant Peripheral Nerve Sheath Tumour (MPNST)1
3Active Not RecruitingTreatmentLeukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive1
3Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute1
3Active Not RecruitingTreatmentMyelogenous Leukemia, Chronic1
3CompletedTreatmentAstrocytomas / Glioblastoma Multiforme1
3CompletedTreatmentBone Marrow Diseases / Hematologic Diseases / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Leukemias / Myeloid Leukemias / Philadelphia Chromosome1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentChronic Myelocytic Leukemia1
3CompletedTreatmentChronic Myelogenous Leukemia (CML)3
3CompletedTreatmentChronic Myelogenous Leukemia in Chronic Phase1
3CompletedTreatmentChronic Myeloid Leukemia (CML)3
3CompletedTreatmentGastrointestinal Stromal Tumors4
3CompletedTreatmentGastrointestinal Stromal Tumors (GISTs)1
3CompletedTreatmentLeukemia, Lymphocytic1
3CompletedTreatmentLeukemia, Myeloid, Chronic, BCR-ABL Positive1
3CompletedTreatmentLeukemia,Myeloid, Chronic1
3CompletedTreatmentLeukemias3
3CompletedTreatmentNephrogenic Systemic Fibrosis1
3CompletedTreatmentPulmonary Arterial Hypertension (PAH)1
3CompletedTreatmentSarcomas1
3Not Yet RecruitingDiagnosticGastrointestinal Stromal Tumors1
3RecruitingPreventionGastrointestinal Stromal Tumors / High Risk of Recurrence / KIT + / KIT Gene Mutation / Non-metastatic / Resected Gastrointestinal Stromal Tumors1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentChronic Myeloid Leukemia (CML)2
3RecruitingTreatmentGraft Versus Host Disease (GVHD)1
3RecruitingTreatmentLeukemia, Myeloid, Chronic-Phase1
3RecruitingTreatmentMyelogenous Leukemia, Chronic1
3RecruitingTreatmentMyeloid Leukemia, Chronic, Chronic Phase1
3RecruitingTreatmentPhiladelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentSarcomas1
3TerminatedTreatmentChronic Myeloid Leukemia (CML)1
3TerminatedTreatmentGastrointestinal Stromal Tumors5
3TerminatedTreatmentLeukemia, Myeloid, Chronic Phase1
3TerminatedTreatmentLeukemias1
3TerminatedTreatmentMyelogenous Leukemia1
3TerminatedTreatmentPulmonary Arterial Hypertension (PAH)3
3Unknown StatusTreatmentCML, CML-CP,MMR,TKI1
3Unknown StatusTreatmentChronic Myeloid Leukemia (CML)2
3Unknown StatusTreatmentGastrointestinal Stromal Tumors3
3Unknown StatusTreatmentLeukemia, Myeloid, Philadelphia-Positive1
3Unknown StatusTreatmentLeukemias1
3Unknown StatusTreatmentLeukemias / Mucositis / Oral Complications1
4Active Not RecruitingOtherChronic Myeloid Leukemia (CML)1
4Active Not RecruitingTreatmentGIST and CML1
4CompletedNot AvailableChronic Myeloid Leukemia (CML)1
4CompletedTreatmentCancer, Breast1
4CompletedTreatmentChronic Myelogenous Leukemia (CML)2
4CompletedTreatmentChronic Myeloid Leukemia (CML)1
4CompletedTreatmentGastrointestinal Stromal Tumors1
4CompletedTreatmentProgressive Gastrointestinal Stromal Tumor1
4CompletedTreatmentSystemic Mastocytosis1
4No Longer AvailableNot AvailableGastrointestinal Stromal Tumors1
4Not Yet RecruitingTreatmentChronic Myeloid Leukemia (CML)1
4Not Yet RecruitingTreatmentChronyc Myeloid Leukemia1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4RecruitingTreatmentAcute Lymphoblastic Leukemia Ph Positive1
Not AvailableAvailableNot AvailableChronic Myeloid Leukemia (CML)1
Not AvailableCompletedNot AvailableAll Indications for Glivec/Gleevec and Tasigna1
Not AvailableCompletedNot AvailableChronic Myeloid Leukemia (CML) / Newly Diagnosed1
Not AvailableCompletedNot AvailableChronic Myeloid Leukemia, Chronic Phase1
Not AvailableCompletedNot AvailableLeukemia, Myeloid, Chronic-Phase (CML-CP)1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentChronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Hypereosinophilic Syndromes / Polycythemia Vera (PV) / Urticaria Pigmentosa1
Not AvailableCompletedTreatmentChronic Myeloid Leukemia (CML) / Gastrointestinal Stromal Tumors1
Not AvailableCompletedTreatmentL1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentLeukemia,Myeloid, Chronic1
Not AvailableCompletedTreatmentLeukemias1
Not AvailableRecruitingNot AvailableChronic Myeloid Leukemia (CML)1
Not AvailableRecruitingTreatmentChronic Myelogenous Leukemia (CML)1
Not AvailableRecruitingTreatmentGastrointestinal Cancers1
Not AvailableTerminatedNot AvailableChronic Myelogenous Leukemia (CML)1
Not AvailableUnknown StatusNot AvailableChronic Myeloid Leukemia (CML)1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg
TabletOral100 mg/1
TabletOral100 mg
TabletOral400 mg/1
TabletOral400 mg
Tablet, film coatedOral100 mg
Tablet, film coatedOral400 mg
CapsuleOral400 mg
CapsuleOral50 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral400 mg/1
Prices
Unit descriptionCostUnit
Gleevec 400 mg tablet174.38USD tablet
Gleevec 100 mg tablet41.69USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2093203No2002-11-262013-04-01Canada
USRE43932Yes1999-07-162019-07-16Us
US7544799Yes1999-07-162019-07-16Us
US6894051Yes1999-11-232019-11-23Us
US6958335Yes2002-06-192022-06-19Us
US5521184Yes1995-07-042015-07-04Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)226 °C (mesylate salt)Not Available
water solubilityVery soluble in water at pH < 5.5 (mesylate salt)Not Available
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0146 mg/mLALOGPS
logP3.47ALOGPS
logP4.38ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)8.27ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.28 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity148.93 m3·mol-1ChemAxon
Polarizability55.54 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9865
Blood Brain Barrier+0.7624
Caco-2 permeable+0.5076
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8107
P-glycoprotein inhibitor IINon-inhibitor0.5326
Renal organic cation transporterInhibitor0.5299
CYP450 2C9 substrateNon-substrate0.8287
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6547
CYP450 1A2 substrateNon-inhibitor0.6602
CYP450 2C9 inhibitorNon-inhibitor0.8813
CYP450 2D6 inhibitorNon-inhibitor0.7933
CYP450 2C19 inhibitorNon-inhibitor0.8516
CYP450 3A4 inhibitorNon-inhibitor0.9313
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7962
Ames testNon AMES toxic0.8134
CarcinogenicityNon-carcinogens0.919
BiodegradationNot ready biodegradable0.9819
Rat acute toxicity2.6013 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7709
hERG inhibition (predictor II)Inhibitor0.8887
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0000900000-3974d719909aa7a75039
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0000900000-dd386ae17930da36c11f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0f6x-0159500000-576f293e026deaa1ec7f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0ik9-0495000000-06102c4afd3c2e88cf87
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03ka-0971000000-b487f693e17cba198e37
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-05fs-0930000000-9319811c561fd5cc8f2f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0159-4910000000-25480eb9451aee843c26
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-0638bee21655c0e0ca00
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-76f9b62b017fe8241e67
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0000900000-9825e12c65f9bf36d72f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-1029200000-acd76280414e767f0280
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-2269000000-f55e5c707c9de5ba2d0f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00ba-3494000000-19e7d8361f050ec8b637
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00ba-3693000000-c1e011113081e3341bba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0596-5981000000-a0f689cd067d45644bcd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f9f-5930000000-71f05e812cf29e11cc69
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00ku-5910000000-3f91ea6a6f7402767a78
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-029i-7900000000-507c771376ea4b799b6d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0191000000-fb24a3158c9475186c82
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0036900000-e06abe669a9b1b57e2c3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-3379600000-f122458b106bcf2c8b8e

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Benzanilides
Alternative Parents
Pyridinylpyrimidines / Benzamides / Diaminotoluenes / Aniline and substituted anilines / Benzoyl derivatives / Benzylamines / Phenylmethylamines / N-methylpiperazines / Aminopyrimidines and derivatives / Aralkylamines
show 11 more
Substituents
Benzanilide / Pyridinylpyrimidine / Benzamide / Benzoic acid or derivatives / Diaminotoluene / Phenylmethylamine / Benzoyl / Benzylamine / Aniline or substituted anilines / Aminopyrimidine
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrimidines, benzamides, pyridines, aromatic amine, N-methylpiperazine (CHEBI:45783)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Not Available
Gene Name
BCR/ABL fusion
Uniprot ID
A9UF02
Uniprot Name
BCR/ABL fusion protein isoform X9
Molecular Weight
179321.835 Da
References
  1. Nadal E, Olavarria E: Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies. Int J Clin Pract. 2004 May;58(5):511-6. [PubMed:15206509]
  2. Waller CF: Imatinib mesylate. Recent Results Cancer Res. 2010;184:3-20. doi: 10.1007/978-3-642-01222-8_1. [PubMed:20072827]
  3. Croom KF, Perry CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs. 2003;63(5):513-22; discussion 523-4. [PubMed:12600228]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Multitarget
General Function
Transmembrane receptor protein tyrosine kinase activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell main...
Gene Name
KIT
Uniprot ID
P10721
Uniprot Name
Mast/stem cell growth factor receptor Kit
Molecular Weight
109863.655 Da
References
  1. Lee JL, Kim JY, Ryu MH, Kang HJ, Chang HM, Kim TW, Lee H, Park JH, Kim HC, Kim JS, Kang YK: Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1. Dig Dis Sci. 2006 Jun;51(6):1043-6. [PubMed:16865565]
  2. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, Schild SE, Jett JR, Adjei AA: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005 Nov;16(11):1811-6. Epub 2005 Aug 8. [PubMed:16087693]
  3. Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Wozniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W: Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. Epub 2007 Apr 26. [PubMed:17458563]
  4. De Giorgi U: KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors. J Clin Oncol. 2007 Mar 20;25(9):1146-7; author reply 1147-8. [PubMed:17369583]
  5. Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N, Premkumar A, Hussain MM, Chang R, Steinberg SM, Kohn EC: A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007 Jul 15;110(2):309-17. [PubMed:17559139]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Not Available
Specific Function
Not Available
Gene Name
RET
Uniprot ID
O43519
Uniprot Name
RET proto-oncogene
Molecular Weight
2129.3 Da
References
  1. de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, Links TP, Eggen BJ, Hofstra RM: Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery. 2006 Jun;139(6):806-14. [PubMed:16782438]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Transmembrane receptor protein tyrosine kinase activity
Specific Function
Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympatheti...
Gene Name
NTRK1
Uniprot ID
P04629
Uniprot Name
High affinity nerve growth factor receptor
Molecular Weight
87496.465 Da
References
  1. Catani M, De Milito R, Simi M: [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. Chir Ital. 2005 Jan-Feb;57(1):127-33. [PubMed:15832750]
  2. Kovacs M, Nagy P, Pak G, Feher J: [Gastrointestinal stromal tumors (GISTs): clinical and pathological features]. Orv Hetil. 2005 Jun 26;146(26):1375-81. [PubMed:16052979]
  3. de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, Links TP, Eggen BJ, Hofstra RM: Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery. 2006 Jun;139(6):806-14. [PubMed:16782438]
  4. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE: A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007 Sep;92(9):3466-9. Epub 2007 Jun 19. [PubMed:17579194]
  5. Delbaldo C: [Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)]. Therapie. 2007 Mar-Apr;62(2):87-90. Epub 2007 Jun 21. [PubMed:17582306]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor ...
Gene Name
CSF1R
Uniprot ID
P07333
Uniprot Name
Macrophage colony-stimulating factor 1 receptor
Molecular Weight
107982.955 Da
References
  1. Dewar AL, Zannettino AC, Hughes TP, Lyons AB: Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle. 2005 Jul;4(7):851-3. Epub 2005 Jul 28. [PubMed:15917650]
  2. Taylor JR, Brownlow N, Domin J, Dibb NJ: FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene. 2006 Jan 5;25(1):147-51. [PubMed:16170366]
  3. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, Zannettino AC: Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006 Jun 1;107(11):4334-7. Epub 2006 Jan 31. [PubMed:16449525]
  4. Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H: Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab. 2006;24(4):274-82. [PubMed:16816921]
  5. El Hajj Dib I, Gallet M, Mentaverri R, Sevenet N, Brazier M, Kamel S: Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol. 2006 Dec 3;551(1-3):27-33. Epub 2006 Sep 16. [PubMed:17049513]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chem...
Gene Name
PDGFRA
Uniprot ID
P16234
Uniprot Name
Platelet-derived growth factor receptor alpha
Molecular Weight
122668.46 Da
References
  1. Yi ES, Strong CR, Piao Z, Perucho M, Weidner N: Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity. Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):157-61. [PubMed:15894928]
  2. Borbenyi Z: [Disorders with eosinophilia, treatment of hypereosinophilic syndrome]. Orv Hetil. 2005 May 1;146(18 Suppl 1):911-6. [PubMed:15921304]
  3. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC: PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005 Aug 10;23(23):5357-64. Epub 2005 May 31. [PubMed:15928335]
  4. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS: Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep. 2005 Jul;7(4):293-9. [PubMed:15946589]
  5. Tefferi A: Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114(1):52-60. [PubMed:15995325]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Transmembrane receptor protein tyrosine kinase activity
Specific Function
Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, dif...
Gene Name
DDR1
Uniprot ID
Q08345
Uniprot Name
Epithelial discoidin domain-containing receptor 1
Molecular Weight
101126.72 Da
References
  1. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE: Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005 Oct 15;106(8):2865-70. Epub 2005 Jun 21. [PubMed:15972446]
  2. Xu L, Tong R, Cochran DM, Jain RK: Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 2005 Jul 1;65(13):5711-9. [PubMed:15994946]
  3. Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, Rochat B, Reichen J: Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol. 2006 Jan;44(1):167-75. Epub 2005 Jul 12. [PubMed:16168515]
  4. Jubert C, Geoerger B, Grill J, Hartmann O, Vassal G: [Targeted therapies in pediatric oncology: a new therapeutic approach?]. Arch Pediatr. 2006 Feb;13(2):189-94. Epub 2005 Nov 17. [PubMed:16298518]
  5. Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B: Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist. 2006 Jan;11(1):9-20. [PubMed:16401709]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Syntaxin binding
Specific Function
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility a...
Gene Name
ABL1
Uniprot ID
P00519
Uniprot Name
Tyrosine-protein kinase ABL1
Molecular Weight
122871.435 Da
References
  1. Hoerth E, Kodym R: Involvment of c-Abl in the radiation-induced inhibition of myoblast differentiation. Int J Radiat Biol. 2004 Oct;80(10):729-36. [PubMed:15799618]
  2. Dewar AL, Zannettino AC, Hughes TP, Lyons AB: Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle. 2005 Jul;4(7):851-3. Epub 2005 Jul 28. [PubMed:15917650]
  3. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Larrayoz MJ, Lahortiga I, Andreu EJ, Marquez J, Beltran de Heredia JM, Odero MD, Prosper F, Calasanz MJ: Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib. Cancer Genet Cytogenet. 2005 Jul 1;160(1):22-6. [PubMed:15949566]
  4. Brueggemeier SB, Wu D, Kron SJ, Palecek SP: Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates. Biomacromolecules. 2005 Sep-Oct;6(5):2765-75. [PubMed:16153117]
  5. Haberler C, Gelpi E, Marosi C, Rossler K, Birner P, Budka H, Hainfellner JA: Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol. 2006 Jan;76(2):105-9. [PubMed:16205964]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Vascular endothelial growth factor binding
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic...
Gene Name
PDGFRB
Uniprot ID
P09619
Uniprot Name
Platelet-derived growth factor receptor beta
Molecular Weight
123966.895 Da
References
  1. Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L: Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res. 2005 Mar 1;65(5):1897-903. [PubMed:15753388]
  2. Jones RL, Judson IR: The development and application of imatinib. Expert Opin Drug Saf. 2005 Mar;4(2):183-91. [PubMed:15794712]
  3. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA: A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005 Mar;90(2):157-63. [PubMed:15803362]
  4. Johnson FM, Saigal B, Donato NJ: Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. J Cell Physiol. 2005 Nov;205(2):218-27. [PubMed:15887238]
  5. Chen J, Rocken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, Malfertheiner P, Ebert MP: The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett. 2006 Feb 28;233(2):328-37. [PubMed:15893416]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Details
1. Serum albumin
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jorgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009 Nov;23(11):1999-2006. doi: 10.1038/leu.2009.166. Epub 2009 Aug 27. [PubMed:19710702]
  2. Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL: Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia. 2010 Apr;24(4):765-70. doi: 10.1038/leu.2010.16. Epub 2010 Feb 11. [PubMed:20147974]
  3. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergstrom CA, Artursson P: Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008 Oct 9;51(19):5932-42. doi: 10.1021/jm8003152. Epub 2008 Sep 13. [PubMed:18788725]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jorgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009 Nov;23(11):1999-2006. doi: 10.1038/leu.2009.166. Epub 2009 Aug 27. [PubMed:19710702]
  2. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956]
  3. Hamada A, Miyano H, Watanabe H, Saito H: Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003 Nov;307(2):824-8. Epub 2003 Sep 15. [PubMed:12975485]
  4. Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004 Dec 1;104(12):3739-45. Epub 2004 Aug 17. [PubMed:15315971]
  5. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662]
  6. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3348-54. doi: 10.1182/blood-2007-10-116236. Epub 2008 Jul 31. [PubMed:18669873]
  7. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 2005 Apr 1;65(7):2577-82. [PubMed:15805252]
  8. Oka M, Fukuda M, Soda H: [Anticancer drugs and ABC transporters]. Gan To Kagaku Ryoho. 2005 May;32(5):585-92. [PubMed:15918555]
  9. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52. Epub 2005 Jul 9. [PubMed:15970668]
  10. Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M: Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet Cytogenet. 2005 Oct 1;162(1):57-62. [PubMed:16157201]
  11. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K: Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther. 2006 Aug;80(2):192-201. [PubMed:16890580]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Tanihara Y, Masuda S, Katsura T, Inui K: Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol. 2009 Nov 1;78(9):1263-71. doi: 10.1016/j.bcp.2009.06.014. Epub 2009 Jun 18. [PubMed:19540211]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004 Apr 1;64(7):2333-7. [PubMed:15059881]
  2. An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42. doi: 10.1517/17425250903228834. [PubMed:19708828]
  3. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jorgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009 Nov;23(11):1999-2006. doi: 10.1038/leu.2009.166. Epub 2009 Aug 27. [PubMed:19710702]
  4. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. doi: 10.1124/dmd.109.031302. Epub 2010 Apr 27. [PubMed:20423956]
  5. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K: Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2. Epub 2004 Jul 13. [PubMed:15251980]
  6. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662]
  7. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 2005 Apr 1;65(7):2577-82. [PubMed:15805252]
  8. Oka M, Fukuda M, Soda H: [Anticancer drugs and ABC transporters]. Gan To Kagaku Ryoho. 2005 May;32(5):585-92. [PubMed:15918555]
  9. Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52. Epub 2005 Jul 9. [PubMed:15970668]
  10. Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y: Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett. 2006 Mar 8;234(1):73-80. Epub 2005 Nov 21. [PubMed:16303243]
  11. Nakanishi T, Shiozawa K, Hassel BA, Ross DD: Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood. 2006 Jul 15;108(2):678-84. Epub 2006 Mar 16. [PubMed:16543472]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Plays an important role in the formation of pulmonary surfactant, probably by transporting lipids such as cholesterol.
Gene Name
ABCA3
Uniprot ID
Q99758
Uniprot Name
ATP-binding cassette sub-family A member 3
Molecular Weight
191360.235 Da
References
  1. Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, Wulf GG: ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica. 2009 Nov;94(11):1528-36. doi: 10.3324/haematol.2009.008631. [PubMed:19880777]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:24